VIDEO: Chemotherapy retains some activity after pancreatic cancer progression on rucaparib
In this video, Timothy Brown, MD, discussed the results of his study on treatment outcomes of patients with platinum-sensitive BRCA or PALB2-mutated pancreatic cancer who have been treated with and progressed on rucaparib.
Brown, chief fellow in the division of hematology and oncology at Penn Medicine, said the small, descriptive study, which evaluated 42 patients and was presented as part of a poster session at ASCO Annual Meeting, found that chemotherapy does retain some activity for this patient population.
"Post-progression on rucaparib, combination chemotherapy still retains some activity,” Brown said. “Clinicians can choose between platinum-based vs. non-platinum-based chemotherapy and tailor this chemotherapy by their patients' performance status and comorbidities."
Collapse
Read more about